The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 26977267)

Published in Facts Views Vis Obgyn on January 01, 2015

Authors

K Papadmitriou1, X B Trinh1, S Altintas1, P A Van Dam1, M T Huizing1, W A A Tjalma1

Author Affiliations

1: Antwerp University Hospital and University of Antwerp, University Multidisciplinary Breast Clinic and Gynecological Oncology Unit, Wilrijkstraat 10, 2650 Edegem, Belgium.

Associated clinical trials:

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer) | NCT01566721

Articles cited by this

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25

Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52

Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol (2011) 4.12

Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol (2013) 2.79

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol (2012) 2.48

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol (2014) 2.37

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol (2013) 2.02

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol (2014) 0.97

Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta (2014) 0.96

Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe. Ann Oncol (2001) 0.87

Clinical pharmacology of trastuzumab. Curr Clin Pharmacol (2008) 0.85

Subcutaneous administration of anticancer agents. Anticancer Res (2014) 0.83

Lean oncology: a new model for oncologists. J Transl Med (2012) 0.79